WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported that over 200,000
81% of subjects reported improvement in chronic pain and overall health Two-thirds of subjects reported decreased use of pain medications Clinically significant improvement in pain relief, sleep, general activity and walking ability WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc.
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported progress in enlisting
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today announced an agreement
WALTHAM, Mass --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported purchases during July 2015 of
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported that Quell, launched in June
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, announced today the launch of the Quell
The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be featured at the APMA Annual Meeting this week in Orlando, Florida .
Quell Commercial Launch Milestone Achieved; Strong Early Shipments WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2015 . The Company operates in two primary markets - wearable
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2015 second quarter financial results before the opening of the market on July 22, 2015 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2015 to discuss its
